Professor Russell Petty
Clinical Professor (Teaching and Research)
Molecular and Clinical Medicine, School of Medicine
Professor Russell Petty is a graduate of University of Dundee School of Medicine and he completed his initial general medical training in Dundee, Newcastle, and Hobart , then specialist and academic training in Medical Oncology in Aberdeen and Auckland. In 2007 he was appointed as a Clinical Senior Lecturer in Medical Oncology at the University of Aberdeen and promoted to Professor of Medical Oncology in 2014 . In September 2015 he was appointed as Professor of Medical Oncology at the University of Dundee and honorary consultant in Medical Oncology in Ninewells Hospital, NHS Tayside.
His main research interests are in clinical and translational research in gastro-oesophageal cancers. He was the chief investigator of the recently completed COG trial which was the first Phase III randomised controlled trial of second line therapy in oesophageal cancer and lead the translational arm TRANSCOG which identified a predictive biomarker for a gefitinib responsive subgroup of tumours. He is a current member of the trial management groups for several UK national clinical trials in gastroesophageal cancer including PLATFORM and GO-2 and the translational research lead for TRANS-GO2 and TRANSCOG2.
Professor Petty is the current speciality adviser in Medical Oncology to the Chief Medical officer in Scotland. He acts as a clinical expert for SMC and NICE and recently contributed to the Scottish Parliament Health and Sport Committee enquiry in to access to new medicines in Scotland and the reform of SMC process for evaluation of new medicines which included the development of the patient and clinician engagement (PACE) process . He is a current member of the NCRN UGI cancers clinical study group and the EORTC gastric cancer task force and a member of the Editorial Board of BMC Cancer.
I am available for media commentary on my research.
Contact Corporate Communications for media enquiries.
Areas of expertise
University researchers have discovered a new way of identifying ‘zombie’ cells which drive aging and age-related diseases such as cancer, cardiac disease and neurodegenerative diseases
Scottish patients diagnosed with one of the least survivable cancers were 13% less likely to receive potentially curative treatment in the post-lockdown period, according to new University of Dundee research.
Chemotherapy services in Scotland resumed far quicker than in other countries after the first UK lockdown and the Covid-19 pandemic has led to improved treatments for cancer patients, according to new University of Dundee research.